#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15882	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2157	732.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1453	1453	C	958	C	881	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29780	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3683	806.6	0	.	n	.	0	T695C	SNP	695	695	T	1121	1121	C	918	C	859	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29780	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3683	806.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1763	1763	A	1066	A	992	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29780	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3683	806.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2397	2397	C	951	C	880	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29780	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3683	806.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2471	2471	A	985	A	925	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29780	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3683	806.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3023	3023	C	892	C	843	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29780	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3683	806.6	0	HET	.	.	.	A2404G	.	2404	2404	A	2830	2830	A	916	A,G	638,219	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2290	folP	852	852	100.0	folP.l15.c4.ctg.1	1510	150.7	1	SNP	p	R228S	1	.	.	682	684	AGC	993	995	AGC	249;251;255	A;G;C	230;233;235	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5950	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3466	171.2	1	SNP	p	S91F	0	.	.	271	273	TCC	676	678	TCC	214;217;218	T;C;C	198;201;201	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5950	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3466	171.2	1	SNP	p	D95G	0	.	.	283	285	GAC	688	690	GAC	211;213;210	G;A;C	192;195;195	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5950	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3466	171.2	1	SNP	p	D95N	0	.	.	283	285	GAC	688	690	GAC	211;213;210	G;A;C	192;195;195	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1842	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1216	150.2	1	SNP	p	G45D	0	.	.	133	135	GGC	468	470	GGC	228;228;228	G;G;C	209;212;212	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	910	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	958	94.3	0	.	n	.	0	A197.	DEL	197	197	A	544	544	A	211	A	204	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5642	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2831	198.3	1	SNP	p	D86N	0	.	.	256	258	GAC	527	529	GAC	243;246;249	G;A;C	217;216;224	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5642	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2831	198.3	1	SNP	p	S87I	0	.	.	259	261	AGT	530	532	AGT	249;247;248	A;G;T	223;223;222	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5642	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2831	198.3	1	SNP	p	S87W	0	.	.	259	261	AGT	530	532	AGT	249;247;248	A;G;T	223;223;222	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5642	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2831	198.3	1	SNP	p	S87R	0	.	.	259	261	AGT	530	532	AGT	249;247;248	A;G;T	223;223;222	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5642	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2831	198.3	1	SNP	p	S88P	0	.	.	262	264	TCC	533	535	TCC	246;248;248	T;C;C	218;224;226	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4872	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2468	195.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1450	1452	GGC	235;234;233	G;G;C	223;222;223	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1237	1239	GCA	208;205;203	G;C;A	190;186;190	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1240	1242	ATC	206;205;211	A;T;C	192;190;194	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1252	1254	GTG	221;221;218	G;T;G	208;207;205	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1252	1254	GTG	221;221;218	G;T;G	208;207;205	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1756	1758	ACC	196;195;199	A;C;C	176;175;179	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1810	1812	GCG	218;219;219	G;C;G	194;172;179	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1810	1812	GCG	218;219;219	G;C;G	194;172;179	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1933	1935	GGC	201;201;199	G;G;C	186;184;183	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1942	1944	GGC	193;189;187	G;G;C	178;172;174	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4256	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2485	170.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1960	1962	CCG	173;175;178	C,G;C;G,GGGC	125,4;127;127,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6086	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3138	193.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2558	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1729	146.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	466	466	C	177	C,G	166,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	331	90.45	porB1a.l15.c30.ctg.2	560	23.5	0	.	p	.	0	H217N	NONSYN	649	651	CAT	238	240	AAT	23;23;23	A;A;T	23;23;23	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	331	90.45	porB1a.l15.c30.ctg.2	560	23.5	0	.	p	.	0	D218N	NONSYN	652	654	GAT	241	243	AAT	23;24;24	A;A;T	23;24;24	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	331	90.45	porB1a.l15.c30.ctg.2	560	23.5	0	.	p	.	0	A222V	NONSYN	664	666	GCT	253	255	GTT	22;21;21	G;T;T	22;21;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	331	90.45	porB1a.l15.c30.ctg.2	560	23.5	0	.	p	.	0	V226A	NONSYN	676	678	GTA	265	267	GCA	20;21;19	G;C;A	19;21;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	331	90.45	porB1a.l15.c30.ctg.2	560	23.5	0	.	p	.	0	.	MULTIPLE	700	702	ACT	288	290	GTA	14;14;14	G;T;A	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	331	90.45	porB1a.l15.c30.ctg.2	560	23.5	0	.	p	.	0	D238fs	FSHIFT	712	712	G	300	300	G	18	G	18	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	478	480	GGA	249;250;253	G;G,A;A	234;235,1;237	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	0	.	p	.	0	F135L	NONSYN	403	405	TTT	739	741	CTT	226;232;230	C;T;T	208;216;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	763	765	GGA	220;219;220	G;G;A	196;198;196	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	0	.	p	.	0	D171G	NONSYN	511	513	GAT	847	849	GGT	205;205;205	G;G;T	191;190;183	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	0	.	p	.	0	G189S	NONSYN	565	567	GGC	901	903	AGC	208;206;205	A;G;C	199;196;195	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	967	967	T	198	T	188	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	1	SNP	p	G120K	0	.	.	358	360	GGT	694	696	GGT	208;208;212	G;G;T	200;201;199	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	1	SNP	p	A121D	0	.	.	361	363	GCC	697	699	GCC	218;219;219	G;C;C	208;211;210	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2766	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1531	180.0	1	SNP	p	A121N	0	.	.	361	363	GCC	697	699	GCC	218;219;219	G;C;C	208;211;210	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	T298A	NONSYN	892	894	ACT	44	46	GCT	5;5;5	G,A;C;T	0,5;5;5	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	E313A	NONSYN	937	939	GAA	89	91	GCA	5;5;5	G;C;A	5;5;5	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	N314D	NONSYN	940	942	AAC	92	94	GAC	5;5;5	G;A;C	5;5;5	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	F316I	NONSYN	946	948	TTC	98	100	ATC	2;2;2	A;T;C	2;2;2	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	A318S	NONSYN	952	954	GCG	104	106	TCG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	G321S	NONSYN	961	963	GGC	113	115	AGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	G322A	NONSYN	964	966	GGT	116	118	GCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	G324V	NONSYN	970	972	GGT	122	124	GTT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	290	porB3	990	141	92.2	porB3.l6.c30.ctg.3	278	5.5	0	.	p	.	0	H327R	NONSYN	979	981	CAC	131	133	CGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10790	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4938	218.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1997	1999	AAT	213;210;211	A,C;A;T	198,1;197;198	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1224	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	839	143.2	1	SNP	p	V57M	1	.	.	169	171	ATG	422	424	ATG	256;258;256	A;T;G	238;241;236	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
